We have read with great interest the recent article by Cheung et al, 1 revealing that matrix metalloproteinase-9 (MMP-9)-deficient mice had increased coxsackievirus B3 (CVB3) replication and resulting inflammation and injury in CVB3-induced myocarditis. 1 These findings were to some extent unexpected considering our previous findings that systemic overexpression of the tissue inhibitor of MMPs (TIMP-1) reduced cardiac inflammation and prevented adverse remodeling and dysfunction in CVB3 myocarditis. 2 To make it even more complicated, inhibition of TIMP-1 significantly decreased inflammation and injury in CVB3-induced myocarditis, despite lack of differences in viral load or T-cell function. 3 What to learn from these seemingly paradoxical studies?
Letter by Pinto and Heymans Regarding Article, "Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice"
To the Editor:
We have read with great interest the recent article by Cheung et al, 1 revealing that matrix metalloproteinase-9 (MMP-9)-deficient mice had increased coxsackievirus B3 (CVB3) replication and resulting inflammation and injury in CVB3-induced myocarditis. 1 These findings were to some extent unexpected considering our previous findings that systemic overexpression of the tissue inhibitor of MMPs (TIMP-1) reduced cardiac inflammation and prevented adverse remodeling and dysfunction in CVB3 myocarditis. 2 To make it even more complicated, inhibition of TIMP-1 significantly decreased inflammation and injury in CVB3-induced myocarditis, despite lack of differences in viral load or T-cell function. 3 What to learn from these seemingly paradoxical studies?
The first question is whether the results are truly discrepant? We demonstrated that a broad inhibition of MMPs, decreased CVB3induced cardiac inflammation and function loss. The now-published report 1 shows that a complete loss of MMP-9 increased replication of CVB3 and thereby resulted in a higher degree of cardiac inflammation and function loss. Thus, the beneficial effect MMP inhibition that we reported is most probably not due to inhibition of MMP-9 activity.
A paradoxical role for selective versus nonspecific MMP inhibition was also observed in cardiac allograft rejection, another T-celldependent disease. Use of a broad spectrum MMP inhibitor significantly reduced T-cell infiltration and improved survival of the cardiac allograft, whereas MMP-9 gene-inactivated mice had significantly increased cellular infiltration and impaired cardiac allograft survival. 4 Whether TIMP-1 deficiency or overexpression also alters cardiac allograft function and survival warrants further investigation.
What about the role of MMP-9 in other cardiac diseases? Independent studies clearly showed that deficiency of MMP-9 but also of MMP-2 significantly reduced inflammation and improved cardiac function after myocardial infarction or hypertension (reviewed in Vanhoutte et al 5 ) . Nonspecific MMP inhibition with synthetic MMP inhibitors or TIMP-1 overexpression reduced adverse cardiac remodeling and failure after myocardial infarction, whereas TIMP-1 deficiency exacerbated left ventricular dilatation after myocardial infarction. A disparate role for MMP-9 in cardiac inflammation in myocardial infarction compared with myocarditis may relate to the different inflammatory cells and cytokines involved and their disparate regulation by MMP-9.
What about TIMP-1 itself? A complete loss of TIMP-1 decreased CVB3-induced cardiac inflammation and function loss, whereas we reported that a short strong systemic increase in TIMP-1 actually decreased CVB3-induced cardiac dilatation and function loss. These findings could be explained by the fact that TIMP-1 plays a function in retaining the inflammatory cells to areas of CVB3 infection, inducing myocarditis, injury, and dysfunction without affecting MMP levels. 3 In contrast, supraphysiological levels of TIMP-1 may prevent the deleterious effect of CVB3-induced MMPs, reducing adverse cardiac dilation.
In conclusion, therapeutic inhibition of MMPs should be restricted for well-specified cardiac diseases with a comprehensive diagnosis of the underlying cause. Thus, specific MMP-2 or -9 inhibitors may be beneficial for the treatment of acute ischemic or hypertensive heart disease, but should be used with care in acute viral myocarditis. 
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